CORVUS PHARMACEUTICALS INC's ticker is CRVS and the CUSIP is 221015100. A total of 49 filers reported holding CORVUS PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 3.61 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $643,303 | -73.3% | 361,406 | -73.6% | 0.02% | -70.0% |
| Q4 2023 | $2,412,867 | +20.5% | 1,370,947 | 0.0% | 0.06% | +11.1% |
| Q3 2023 | $2,001,583 | -36.2% | 1,370,947 | 0.0% | 0.05% | -38.6% |
| Q2 2023 | $3,139,469 | +151.6% | 1,370,947 | 0.0% | 0.09% | +91.3% |
| Q1 2023 | $1,247,562 | +7.1% | 1,370,947 | 0.0% | 0.05% | -6.1% |
| Q4 2022 | $1,165,305 | +3.9% | 1,370,947 | 0.0% | 0.05% | +6.5% |
| Q3 2022 | $1,122,000 | -17.3% | 1,370,947 | 0.0% | 0.05% | -30.3% |
| Q2 2022 | $1,357,000 | -39.6% | 1,370,947 | 0.0% | 0.07% | -26.7% |
| Q1 2022 | $2,248,000 | -32.0% | 1,370,947 | 0.0% | 0.09% | -25.0% |
| Q4 2021 | $3,304,000 | -50.2% | 1,370,947 | 0.0% | 0.12% | -53.7% |
| Q3 2021 | $6,635,000 | -32.4% | 1,370,947 | -62.7% | 0.26% | -29.6% |
| Q2 2021 | $9,822,000 | -1.3% | 3,678,626 | +13.9% | 0.37% | -1.3% |
| Q1 2021 | $9,947,000 | +43.7% | 3,229,426 | +66.1% | 0.37% | +37.1% |
| Q4 2020 | $6,920,000 | -1.0% | 1,943,712 | +11.5% | 0.27% | -28.6% |
| Q3 2020 | $6,992,000 | +47.5% | 1,743,712 | +0.1% | 0.38% | +30.5% |
| Q2 2020 | $4,739,000 | +4.1% | 1,742,112 | -19.2% | 0.29% | -31.1% |
| Q1 2020 | $4,551,000 | -48.6% | 2,156,740 | +32.5% | 0.42% | -36.8% |
| Q4 2019 | $8,854,000 | -3.5% | 1,627,568 | -46.6% | 0.67% | -30.4% |
| Q3 2019 | $9,172,000 | -11.6% | 3,047,155 | +9.8% | 0.96% | -14.9% |
| Q2 2019 | $10,378,000 | +22.4% | 2,774,750 | +31.5% | 1.13% | +19.3% |
| Q1 2019 | $8,480,000 | +22.2% | 2,109,342 | +11.6% | 0.95% | +4.7% |
| Q4 2018 | $6,938,000 | -57.2% | 1,890,507 | 0.0% | 0.91% | -36.4% |
| Q3 2018 | $16,221,000 | -21.9% | 1,890,507 | 0.0% | 1.42% | -29.7% |
| Q2 2018 | $20,758,000 | -7.9% | 1,890,507 | -3.3% | 2.03% | -11.3% |
| Q1 2018 | $22,533,000 | +373.5% | 1,954,254 | +325.4% | 2.28% | +297.9% |
| Q4 2017 | $4,759,000 | -35.0% | 459,396 | 0.0% | 0.57% | -38.3% |
| Q3 2017 | $7,323,000 | +120.7% | 459,396 | +67.5% | 0.93% | +80.8% |
| Q2 2017 | $3,318,000 | – | 274,196 | – | 0.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ADAMS STREET PARTNERS LLC | 2,687,381 | $38,430,000 | 10.58% |
| Novo Holdings A/S | 3,224,046 | $46,104,000 | 4.39% |
| SPHERA FUNDS MANAGEMENT LTD. | 320,229 | $4,579,000 | 1.16% |
| Orbimed Advisors | 5,379,349 | $76,925,000 | 0.98% |
| Avoro Capital Advisors LLC | 216,619 | $3,098,000 | 0.63% |
| Rock Springs Capital Management LP | 450,000 | $6,435,000 | 0.43% |
| Cormorant Asset Management, LP | 198,526 | $2,839,000 | 0.38% |
| EverPoint Asset Management, LLC | 417,849 | $5,975,000 | 0.11% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 21,292 | $304,000 | 0.05% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 9,402 | $134,000 | 0.02% |